About half of women whose breast cancer is treated with standard chemotherapy have their cancer return within five years. Most chemotherapeutic drugs have undesirable side effects, but there has been no way to predict who would benefit and who wouldn't. Fortunately, new research findings at the University of Southern California could change that.
Researchers at the USC/Norris Comprehensive Cancer Center have discovered a new biological marker in tumors that can help indicate whether a woman's breast cancer will respond to the most commonly prescribed chemotherapy drugs.
Amy S. Lee, Ph.D., professor of biochemistry and molecular biology in the Keck School of Medicine of the University of Southern California, isolated the gene for the GRP78 protein (78-kDA glucose-regulated protein) in 1980. It normally helps protect cells from dying, particularly when they are under stress from a lack of glucose. In her current research, Lee finds that breast cancer tumors with high levels of GRP78 are protected from a common chemotherapy regimen based on Adriamycin, a topoisomerase inhibitor. Her findings are published as a "Priority Report" in the August 15 issue of Cancer Research.
"The importance of this study is in its potential to help clinicians who treat cancer," Lee says. "It will help sort out the patients who won't respond to particular treatment regimens and will have a higher chance of cancer recurrence."
Lee and her colleagues analyzed records of 432 women with Stage II or III breast cancer treated at the USC/Norris Cancer Hospital, of whom 209 received Adriamycin-based chemotherapy. Tumor samples were collected from 127 of the women before they received chemotherapy. The samples were analyzed using antibodies to detect and stain GRP78 protein. Review of the samples under a microscope showed that two-thirds (67 percent) of the tumors tested had high levels of GRP78.
Subsequent analysis of the patients' records showed that women whose tumors had higher levels of GRP78 were more likely to have had the cancer recur. That was particularly likely if the women received Adriamycin-based chemotherapy and no further treatment with the chemotherapy drug taxane, regardless of their tumor stage. Likewise, women who had mastectomies followed by Adriamycin-based therapy were more likely to have the cancer return if their tumors had elevated levels of GRP78, compared to identically treated patients with low level of GRP78.
Conversely, the study also suggests that women who received Adriamycin-based therapy followed by additional treatment with taxane had a lower risk of cancer recurrence if their tumors had elevated levels of GRP78.
Lee hopes others will confirm her findings in subsequent research, and that it will eventually lead to a standard laboratory test that can screen all women diagnosed with breast cancer. "GRP78 will be one more bio-marker to help us offer designer medicine – treatments that are tailored to the patient's cancer instead of one-size-fits-all," Lee says.
The study is anticipated to have broad implications since other types of cancers have also been found to have elevated levels of GRP78. To that end, Lee is also collaborating with USC/Norris pathologist Richard Cote, M.D., on a study of the protein's role in prostate cancer.
Lee says the access to specialists from various disciplines was essential. "This research could not have happened without the collaborative environment at the USC/ Norris Comprehensive Cancer Center," she says. Lee's interdisciplinary research team included clinical oncologist Darcy Spicer, M.D., pathologist Peter Nichols, M.D., epidemiologist Mimi C. Yu, Ph.D., biostatistician Susan Groshen, Ph.D., and epidemiology Ph.D. student Eunjung Lee.
Kathleen O'Neil | EurekAlert!
Closing the carbon loop
08.12.2016 | University of Pittsburgh
Newly discovered bacteria-binding protein in the intestine
08.12.2016 | University of Gothenburg
In recent years, lasers with ultrashort pulses (USP) down to the femtosecond range have become established on an industrial scale. They could advance some applications with the much-lauded “cold ablation” – if that meant they would then achieve more throughput. A new generation of process engineering that will address this issue in particular will be discussed at the “4th UKP Workshop – Ultrafast Laser Technology” in April 2017.
Even back in the 1990s, scientists were comparing materials processing with nanosecond, picosecond and femtosesecond pulses. The result was surprising:...
Have you ever wondered how you see the world? Vision is about photons of light, which are packets of energy, interacting with the atoms or molecules in what...
A multi-institutional research collaboration has created a novel approach for fabricating three-dimensional micro-optics through the shape-defined formation of porous silicon (PSi), with broad impacts in integrated optoelectronics, imaging, and photovoltaics.
Working with colleagues at Stanford and The Dow Chemical Company, researchers at the University of Illinois at Urbana-Champaign fabricated 3-D birefringent...
In experiments with magnetic atoms conducted at extremely low temperatures, scientists have demonstrated a unique phase of matter: The atoms form a new type of quantum liquid or quantum droplet state. These so called quantum droplets may preserve their form in absence of external confinement because of quantum effects. The joint team of experimental physicists from Innsbruck and theoretical physicists from Hannover report on their findings in the journal Physical Review X.
“Our Quantum droplets are in the gas phase but they still drop like a rock,” explains experimental physicist Francesca Ferlaino when talking about the...
The Max Planck Institute for Physics (MPP) is opening up a new research field. A workshop from November 21 - 22, 2016 will mark the start of activities for an innovative axion experiment. Axions are still only purely hypothetical particles. Their detection could solve two fundamental problems in particle physics: What dark matter consists of and why it has not yet been possible to directly observe a CP violation for the strong interaction.
The “MADMAX” project is the MPP’s commitment to axion research. Axions are so far only a theoretical prediction and are difficult to detect: on the one hand,...
16.11.2016 | Event News
01.11.2016 | Event News
14.10.2016 | Event News
08.12.2016 | Life Sciences
08.12.2016 | Physics and Astronomy
08.12.2016 | Materials Sciences